CLINICAL TRIAL TO STUDY THE EFFECTS OF DRUGS â??PANCHAMUGA CHENDHURAMâ?? (INTERNAL) AND â??KUNDAVAATHI THAILAMâ?? (EXTERNAL)IN PSORIASIS PATIENTS.

AN OPEN PILOT STUDY ON THADIPPU PERUNOI (PSORIASIS) WITH THE TRIAL DRUG â??PANCHAMUGA CHENDHURAMâ?? (INTERNAL) AND â??KUNDAVAATHI THAILAMâ?? (EXTERNAL).

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/07/004758

Enrollment

Registered

2014-07-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PSORIASIS

Interventions

Intervention1: PANCHAMUGA CHENDHURAM(internal), KUNDAVAATHI THAILAM(external): 20 patients treated with both PANCHAMUGA CHENDHURAM(internal), KUNDAVAATHI THAILAM(external). PANCHAMUGA CHENDHURAM,50 mg

Eligibility

Inclusion criteria

Inclusion criteria: Patches with Scaling. Auspitz Sign + Koebnerâ??s Phenomenon + Willing to give specimen of blood for the investigation whenever required. Willing to give photographs before and after treatment (Ensuring confidentiality)

Exclusion criteria

Exclusion criteria: Hypertension,Diabetes mellitus,Narcotic addicts,Psoriatic arthropathica,Cardiac disease Leprosy,Peptic ulcer,SLE,progressive systemic sclerosis,Evidences of secondary infection in the lesions,Pregnancy, lactation,HIV

Design outcomes

Primary

Measure	Time frame
Primary outcome is mainly assessed by reduction in clinical symptoms like itching and scaling. PASI Score (Psoriasis area severity index) Timepoint: 12 months	—

Secondary

Measure	Time frame
â?¢ Secondary outcome is assessed by comparing the safety parameters before and after treatment.Timepoint: 12 months	—

Countries

India

Contacts

Public ContactDr M MOHAMED MUSTHAFA

GOVERMENT SIDDHA MEDICAL COLLEGE, CHENNAI.

dr.rajibsms23@gmail.com9585600845

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026